Mass General taps Medrad for lung PET imaging research

TriMed Staff | | Health Imaging | Practice Management
Medical device provider Medrad and Massachusetts General Hospital (MGH) in Boston have entered into an agreement that will aid the hospital with its research in lung function using PET imaging.

Via the terms of the agreement, MGH will pilot a device that will process and inject N13 gas and dissolved in saline for research in both pre-clinical and clinical PET studies by way of Medrad’s controlled fluid delivery technology and programming interface capabilities.

According to the Warrendale, Pa.-based company, the technique will enable acquisition of spatially co-registered functional images of lung perfusion and ventilation in a single procedure.

TriMed Staff

Related Content

MRI accident has prompted the company that installed the scanner to issue a safety warning
Newly launched report feature provides patients with a visual aid to their imaging
Center for Devices and Radiological Health hit with federal job cuts
Overview of the regulatory landscape of AI in radiology
Concerns about private equity's growing influence in radiology
'Ad hoc' shifts and radiology 'maestros': How one department addressed its workflow hiccups

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.